caption: Phase III trial of first-line bevacizumab in MBC (E2100): conclusions and future directions Addition of bevacizumab to paclitaxel Significantly prolongs progression-free survival Increases objective response rate Longer follow-up required to assess impact on overall survival Further studies should Explore the role of bevacizumab in the adjuvant setting Develop methods to identify patients who are most likely to benefit from VEGF-targeted therapies Miller KD, et al.
exif: {}